Vitamin D Management in Patients with Allergic Disease and Deficiency

Initial Repletion Protocol

• Administer 50,000 IU of vitamin D₂ or vitamin D₃ once weekly for 8 weeks (equivalent to ≈6,000 IU daily) to raise serum 25‑hydroxyvitamin D above 30 ng/mL in adult patients. The Endocrine Society recommends this regimen for correcting deficiency. 1, 2, 3
• This dosing reliably corrects deficiency and maintains serum 25‑hydroxyvitamin D concentrations in the 35–50 ng/mL range without evidence of toxicity. 1, 3

Maintenance Therapy

• After successful repletion, continue with a daily dose of 1,500–2,000 IU of vitamin D₂/D₃ to prevent recurrence of deficiency in the general allergic‑disease population. 1, 2, 3
• Re‑measure serum 25‑hydroxyvitamin D 3–6 months after initiating maintenance therapy to verify that target levels (>30 ng/mL) are sustained. 4

Special Populations Requiring Higher Doses

• Patients who are obese, have malabsorption syndromes, or are receiving medications that accelerate vitamin D metabolism (e.g., systemic or inhaled corticosteroids) should receive 2–3 times the standard dose: 6,000–10,000 IU daily during the repletion phase. 1, 5, 2
• For these high‑risk groups, maintenance dosing should be increased to 3,000–6,000 IU daily to keep 25‑hydroxyvitamin D above 30 ng/mL. 1, 5, 2

Clinical Monitoring

• Obtain a baseline serum 25‑hydroxyvitamin D level before starting supplementation. 1, 4
• Re‑check 25‑hydroxyvitamin D 2 weeks after completing the 8‑week repletion course or 3–6 months after initiating maintenance therapy to adjust dosing as needed. 4
• In patients with conditions predisposing to hypercalcemia, monitor serum calcium concurrently with vitamin D levels. 1, 2

Non‑Responder Evaluation

• If serum 25‑hydroxyvitamin D fails to rise despite documented adherence, evaluate for underlying malabsorption disorders such as celiac disease or occult cystic fibrosis. 1, 3
• Confirmed malabsorption warrants escalation to the higher‑dose regimens described above. 1, 5

Corticosteroid Interaction

• Individuals on glucocorticoids—including inhaled or intranasal formulations commonly used for allergic disease—experience enhanced catabolism of both 25‑hydroxyvitamin D and 1,25‑dihydroxyvitamin D, necessitating the higher dosing strategies outlined for special populations. 5, 6, 7

Granulomatous Disorders and Hypercalcemia Risk

• Patients with granulomatous diseases (e.g., sarcoidosis, tuberculosis) are at risk for unregulated 1,25‑dihydroxyvitamin D production by activated macrophages; therefore, vitamin D therapy should be accompanied by close monitoring of both 25‑hydroxyvitamin D and calcium. Target serum 25‑hydroxyvitamin D of 20–30 ng/mL rather than >30 ng/mL to minimize hypercalciuria and hypercalcemia. 1, 5, 6, 7

Vitamin D Formulation Choice

• Either vitamin D₂ (ergocalciferol) or vitamin D₃ (cholecalciferol) may be used for repletion and maintenance; both formulations demonstrate equivalent efficacy in raising serum 25‑hydroxyvitamin D levels. 2, 1

Practical Clinical Algorithm (Summary)

Evidence‑Based Vitamin D Dosing Recommendations

High‑Risk Conditions Requiring Higher Repletion Doses

• Patients with malabsorption syndromes such as celiac disease, inflammatory bowel disease, or a history of gastric bypass should receive 2–3 times the standard repletion dose (approximately 6,000–10,000 IU of vitamin D daily for 8 weeks) to achieve adequate serum 25‑hydroxyvitamin D levels. 8

Preferred Maintenance Strategy

• For long‑term maintenance, daily lower‑dose vitamin D supplementation is recommended over intermittent high‑dose bolus regimens, as daily dosing provides more stable serum concentrations and better safety profile. 8